AVXL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVXL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-11), Anavex Life Sciences's current share price is $3.81. Anavex Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.93. Anavex Life Sciences's Cyclically Adjusted PB Ratio for today is 4.10.
The historical rank and industry rank for Anavex Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Anavex Life Sciences's highest Cyclically Adjusted PB Ratio was 11.22. The lowest was 0.00. And the median was 0.00.
AVXL's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Anavex Life Sciences's adjusted book value per share data for the three months ended in Dec. 2023 was $1.652. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.93 for the trailing ten years ended in Dec. 2023.
The historical data trend for Anavex Life Sciences's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 13.46 | 11.30 | 9.82 | 7.38 | 10.00 |
For the Biotechnology subindustry, Anavex Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Anavex Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 3.81 | / | 0.93 | |
= | 4.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Anavex Life Sciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 1.652 | / | 129.4194 | * | 129.4194 | |
= | 1.652 |
Current CPI (Dec. 2023) = 129.4194.
Anavex Life Sciences Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 0.879 | 99.695 | 1.141 |
201406 | 0.775 | 100.560 | 0.997 |
201409 | 0.016 | 100.428 | 0.021 |
201412 | 0.035 | 99.070 | 0.046 |
201503 | 0.290 | 99.621 | 0.377 |
201506 | 0.305 | 100.684 | 0.392 |
201509 | 0.400 | 100.392 | 0.516 |
201512 | 0.332 | 99.792 | 0.431 |
201603 | 0.271 | 100.470 | 0.349 |
201606 | 0.215 | 101.688 | 0.274 |
201609 | 0.174 | 101.861 | 0.221 |
201612 | 0.472 | 101.863 | 0.600 |
201703 | 0.519 | 102.862 | 0.653 |
201706 | 0.556 | 103.349 | 0.696 |
201709 | 0.560 | 104.136 | 0.696 |
201712 | 0.575 | 104.011 | 0.715 |
201803 | 0.504 | 105.290 | 0.620 |
201806 | 0.520 | 106.317 | 0.633 |
201809 | 0.486 | 106.507 | 0.591 |
201812 | 0.367 | 105.998 | 0.448 |
201903 | 0.294 | 107.251 | 0.355 |
201906 | 0.342 | 108.070 | 0.410 |
201909 | 0.385 | 108.329 | 0.460 |
201912 | 0.455 | 108.420 | 0.543 |
202003 | 0.423 | 108.902 | 0.503 |
202006 | 0.411 | 108.767 | 0.489 |
202009 | 0.439 | 109.815 | 0.517 |
202012 | 0.691 | 109.897 | 0.814 |
202103 | 1.083 | 111.754 | 1.254 |
202106 | 2.076 | 114.631 | 2.344 |
202109 | 1.987 | 115.734 | 2.222 |
202112 | 1.922 | 117.630 | 2.115 |
202203 | 1.973 | 121.301 | 2.105 |
202206 | 1.934 | 125.017 | 2.002 |
202209 | 1.828 | 125.227 | 1.889 |
202212 | 1.732 | 125.222 | 1.790 |
202303 | 1.809 | 127.348 | 1.838 |
202306 | 1.803 | 128.729 | 1.813 |
202309 | 1.729 | 129.860 | 1.723 |
202312 | 1.652 | 129.419 | 1.652 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Anavex Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher U Missling | director, officer: President, CEO, CFO, Treasurer, other: Secretary | 61 MOULTON ST, CAMBRIDGE MA 02138 |
Athanasios Skarpelos | 10 percent owner | 14,RUE KLEBERG, GENEVA V8 CH-1201 |
Jiong Ma | director | 445 PARK AVENUE, 9TH FLOOR, NEW YORK NY 10022 |
Elliot Favus | director | 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10091 |
Donhauser Peter D.o. | director | REGINA-KIRCHMAIER STRASSE 4, KAUFBEUREN 2M 87600 |
Sandra Boenisch | officer: PFO & Treasurer | 51 WEST 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
Claus Vander Velden | director | PO BOX MUENSTEREIFELER ST., COLOGNE 2M 50937 |
Steffen Thomas | director | FALLMERAYER STR. 19, MUNICH 2M 80796 |
Bernd Metzner | director | 51 W 52ND STREET, 7TH FLOOR, NEW YORK NY 10019 |
George F Tidmarsh | director, officer: Executive Director | |
John Robert Chisholm | director | 16308 36A AVENUE, SURREY A1 V3S 0X5 |
William Sean Lowry | director | 1172 BAY STREET, SUITE 300, ONTARIO Z4 M5S1L9 |
David L. Tousley | director | 14610 PAWNEE LANE, LEAWOOD KS 66224 |
Harvey Lalach | director, officer: President CEO CFO | 4837 CANYON RIDGE CRESENT, KELOWNA A1 V1W 4A1 |
Alison E. Ayers | director | 27 O'CONNOR CIRCLE, WEST ORANGE NJ 07052 |
From GuruFocus
By Marketwired • 09-12-2023
By sperokesalga sperokesalga • 03-30-2023
By Marketwired • 09-14-2023
By Stock market mentor Stock market mentor • 02-07-2023
By sperokesalga sperokesalga • 06-06-2023
By Stock market mentor Stock market mentor • 02-02-2023
By Value_Insider Value_Insider • 12-02-2022
By Value_Insider Value_Insider • 12-02-2022
By Value_Insider Value_Insider • 12-14-2022
By Value_Insider Value_Insider • 11-28-2022